Elutia vs Scilex
ELUT and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELUT and SCLX compare
Elutia is the larger company, worth 2.7 times as much as Scilex ($36.3M against $13.2M).
Elutia grew revenue faster over the last twelve months (79.4% versus −28.5% for Scilex).
Elutia keeps more of each dollar of sales as profit, with a net margin of 321% compared with −1470% at Scilex.
Elutia scores higher on the StockData Score (8 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELUT | SCLX |
|---|---|---|
| Size and price | ||
| Market cap | $36.3M | $13.2M |
| Share price | $0.820 | $1.56 |
| Change, 1 year | 10.8% | −91.7% |
| Change, 5 years | −85.9% | −99.6% |
| Beta (5Y) | 0.25 | 0.80 |
| Employees | 26 | 34 |
| StockData Score | ||
| Total score | 8 (better) | 1 |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× | 0.4× (better) |
| P/B | 2.4× | – |
| FCF yield | −140% | – |
| Fair value | $1.05 | – |
| Margin of safety | 21.9% | – |
| Growth | ||
| Revenue growth (TTM) | 79.4% (better) | −28.5% |
| Revenue growth, 5Y average | −22.0% | 5.1% (better) |
| Profitability | ||
| Gross margin | 57.7% | 161% (better) |
| Operating margin | −152% (better) | −1136% |
| Net margin | 321% (better) | −1470% |
| FCF margin | −299% | – |
| Financial health | ||
| Debt / equity | 0.53 | – |
| Interest coverage | – | −22.2× |
| Current ratio | 2.63 (better) | 0.07 |
| Altman Z-score | −5.70 (better) | −12.74 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.8% | 9.8% |
| Held by insiders | 52.0% | – |
| Insider net buying, 12 months | $212K (better) | −$12.8M |
| Short interest, % of float | 0.16% | – |
Go deeper
- ELUT stock overview
- ELUT income statement
- ELUT valuation and score
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.